Oncology

Back to articles

STI571 Provides Dramatic Response in Chronic Myelogenous Leukemia

KEY POINT

In 83 patients with chronic myeloid leukemia (CML) in the chronic phase who had already failed standard interferon alfa therapy, 98% of patients responded completely to doses of STI571 (Gleevec—Novartis) of 300 mg or more. Experts believe that this agent may prove to be a breakthrough treatment for chronic phase CML.

SOURCES

Druker BJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;334:1031–7.

Goldman JM et al. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;334:1084–6.